News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
The Efficacy and Safety of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive Ovarian Cancer – Annals of Oncology
A. Alvarez Secord/dukecancerinstitute.org
Dec 3, 2024, 17:07

The Efficacy and Safety of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive Ovarian Cancer – Annals of Oncology

Annals of Oncology shared a recent article by A. Alvarez Secord on X:

“New article in press: The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial.”

Title: The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial

Authors: A. Alvarez Secord, S.N. Lewin, C.G. Murphy, S.C. Cecere, A. Barquín, F. Gálvez-Montosa, C.A. Mathews, G.E. Konecny, I. Ray-Coquard, A. Oaknin, M. J. Rubio Pérez, A. Bonaventura, E.J. Diver, S.-A. Ayuk, Y. Wang, B.R. Corr and V. Salutari

Mirvetuximab Soravtansine

Mirvetuximab Soravtansine

More posts featuring Annals of Oncology.

A. Alvarez Secord A. Barquín Annals of Oncology B.R. Corr C.A. Mathews C.G. Murphy cancer E.J. Diver efficacy F. Gálvez-Montosa G.E. Konecny Mirvetuximab Soravtansine OncoDaily Oncology Ovarian Cancer PICCOLO Trial Platinum-Sensitive S.-A. Ayuk S.C. Cecere S.N. Lewin safety V. Salutari Y. Wang
Special Coverage
Insight
Dec 3, 2024, 17:07
The Efficacy and Safety of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive Ovarian Cancer - Annals of Oncology
Blog
Dec 3, 2024, 17:06
Lacy Hubbard: Discussing the Nation’s Bold Mission 2027—The Goal to Eliminate Cervical Cancer by 2027
Blog
Dec 3, 2024, 17:01
Jeliazko Arabadjiev: Current Systemic Options for HER2-positive Breast Cancer
Insight
Dec 3, 2024, 16:44
5-year results of the OPERA trial - Organ Preservation in Early cT2–cT3 Rectal Adenocarcinoma
Blog
Dec 3, 2024, 16:31
Abstracts are now being accepted for the upcoming IPSON conference - IPOS
Insight
Dec 3, 2024, 16:22
Norbert Galldiks: Identifying Metabolic Responders to Vorasidenib in IDH-Mutant Gliomas
Opinion
Dec 3, 2024, 16:21
Have faith in yourself, and look out for the bad man - reflections from Neil Ranasinghe's involvement in LGCW
Blog
Dec 3, 2024, 16:17
Emad Shash: Uniting for a better patient journey in Breast Cancer Care
OncoDaily Pulse
Dec 3, 2024, 16:10
Join OncoDaily Now: Apply as a Volunteer
Career
Dec 3, 2024, 15:47
Arturo LoAIza-Bonilla appointed as Systemwide Chief of Hematology and Oncology at St. Luke's University Health Network
Insight
Dec 3, 2024, 15:37
Novocure Announced Positive Topline Results from Phase 3 PANOVA-3 Trial
Insight
Dec 3, 2024, 15:29
Nicholas Robert: Community Oncology Is Driving the Future of Cancer Research